Search results
Tricare Lowers Age for Colon Cancer Screenings to 45
Military.com via Yahoo News· 2 weeks agoTricare beneficiaries at average risk for colorectal cancer can now receive covered screening exams and lab tests five years sooner, at age 45, following...
It may be safe for some to wait 15 years for repeat colonoscopy, study suggests
NBC News via Yahoo News· 1 week agoNew research suggests average-risk patients may only need to get a colonoscopy for colorectal cancer...
Geneoscopy Nabs FDA Approval for Stool-Based Colorectal Cancer Screening Test
GenomeWeb News· 5 days agoOncology diagnostics firm Geneoscopy said Tuesday that the US Food and Drug Administration has approved its noninvasive, stool-based colorectal cancer screening ...
New Day Diagnostics Aims to Enter CRC Screening Market With Combined PCR, Immunoassay Test
GenomeWeb News· 6 days agoWith technologies brought under one roof through a pair of deals last summer, New Day Diagnostics aims to complete within the next two years the development of a blood-based screening
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 days agoThe company's flagship product, Cologuard, is the first FDA-approved non-invasive stool-based DNA...
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by California Public Employees Retirement System
ETF DAILY NEWS· 2 weeks agoCalifornia Public Employees Retirement System lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 3.0% in the fourth quarter, according to the company in its ...
Exact Sciences (NASDAQ:EXAS) Hits New 12-Month Low on Analyst Downgrade
ETF DAILY NEWS· 1 day agoExact Sciences Co. (NASDAQ:EXAS – Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday after Canaccord Genuity Group lowered their price target on the stock from ...
Van ECK Associates Corp Sells 9,078 Shares of Exact Sciences Co. (NASDAQ:EXAS)
ETF DAILY NEWS· 1 week agoVan ECK Associates Corp trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 6.1% in the 4th quarter, according to the company in its most recent Form 13F filing ...